South Carolina Multistate Pharmacy Jurisprudence Examination (MPJE) Practice Exam

True or False: RX vial labels must include an FDA MedWatch disclaimer.

1. True

2. False

3. Only for controlled substances

4. Only for prescription opioids

The correct answer is: True

The requirement for RX vial labels to include an FDA MedWatch disclaimer is an important aspect of pharmacy practice that emphasizes medication safety and reporting of adverse effects. The FDA MedWatch program facilitates reporting of adverse events, product quality problems, and therapeutic inequivalence. Including a disclaimer on RX vial labels serves to remind patients and caregivers of the importance of reporting any problems related to the medications they receive. As such, requiring the MedWatch disclaimer on all RX vial labels, not just those for controlled substances or prescription opioids, aligns with broader goals of promoting patient safety and awareness. This practice contributes to a more informed patient population, enabling them to participate actively in their healthcare decisions and report any adverse reactions they may encounter. In summary, the inclusion of the FDA MedWatch disclaimer on RX vial labels is a vital practice that fosters patient safety and encourages the reporting of adverse medication effects, making the statement true.